Prevalence of periapical abscesses in patients with systemic lupus erythematosus.
apical pathosis
glucocorticoids
lupus erythematosus
periapical abscess
systemic lupus erythematosus
Journal
Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
ISSN: 1754-4505
Titre abrégé: Spec Care Dentist
Pays: United States
ID NLM: 8103755
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
09
03
2021
accepted:
14
06
2021
pubmed:
10
7
2021
medline:
8
1
2022
entrez:
9
7
2021
Statut:
ppublish
Résumé
To assess the prevalence of periapical abscesses in patients with systemic lupus erythematosus (SLE), and to evaluate the effect of glucocorticoids (GCs) used to treat SLE, on the prevalence of such lesions. Integrated data of hospital patients was used. Data from the corresponding diagnosis codes for SLE and periapical abscess was retrieved by searching the appropriate query in the database. The odd ratio (OR) of periapical abscesses and its association with SLE and intake of GCs were calculated and analyzed statistically. The prevalence of periapical abscesses in patients treated with GCs was 1.5% compared to 0.39% in patients who were not treated with GCs. The OR for periapical abscesses in patients treated with GCs was 2.53 compared with OR of 0.66 in patients not treated with GCs. The differences were statistically significant (p < .0001). The prevalence of periapical abscesses in patients with SLE was 1.88%. The OR was 3.18 and the difference statistically significant (p < .0001). Under the conditions of this study, it appears that the prevalence of periapical abscesses is higher in patients with SLE. Patients receiving GCs therapy, either for SLE or for other conditions, may present higher prevalence of periapical abscesses.
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Pagination
15-19Informations de copyright
© 2021 Special Care Dentistry Association and Wiley Periodicals LLC.
Références
Zucchi D, Elefante E, Calabresi E, et al. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37:715-722.
Mok CC, Ho LY, Cheung MY, Yu KL, To CH. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2009;38:121-127.
Prokunina L, Alarcon-Riquelme M. The genetic basis of systemic lupus erythematosus-knowledge of today and thoughts for tomorrow. Hum Mol Genet. 2004;13(Spec No 1):R143-R148.
Ling GS, Crawford G, Buang N, et al. C1q restrains autoimmunity and viral infection by regulating CD8+ T cell metabolism. Science. 2018;360:558-563.
Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford). 2017;56(supp 1):i3-i13.
Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther. 2013;15:218.
Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556-562.
Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE?. Int J Rheum Dis. 2015;18:182-191.
Medlin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2016;45:691-697.
Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol. 2013;32:1053-1058.
Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging. 2012;29:181-189.
Tsang-A-Sjoe MW, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015;16:2793-2806.
Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018;30:482-489.
Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. 2018;37:2081-2086.
Huang YF, Chang YS, Chen WS, et al. Incidence and risk factors of osteomyelitis in adult and pediatric systemic lupus erythematosus: a nationwide, population-based cohort study. Lupus. 2019;28(1):19-26.
Mutlu S, Richards A, Maddison P, Scully C. Gingival and periodontal health in systemic lupus erythematosus. Community Dent Oral Epidemiol. 1993;21:158-161.
Kobayashi T, Ito S, Yamamoto K, et al. Risk of periodontitis in systemic lupus erythematosus is associated with Fcgamma receptor polymorphisms. J Periodontol. 2003;74:378-384.
Corrêa JD, Calderaro DC, Ferreira GA, et al. Subgingival microbiota dysbiosis in systemic lupus erythematosus: association with periodontal status. Microbiome. 2017;5:34.
Rutter-Locher Z, Smith TO, Giles I, Sofat N. Association between Systemic Lupus Erythematosus and Periodontitis: a Systematic Review and Meta-analysis. Front Immunol. 2017;8:1295.
Graves DT, Corrêa JD, Silva TA. The Oral Microbiota Is Modified by Systemic Diseases. J Dent Res. 2019;98:148-156.
Gu C, Zhao R, Zhang X, et al. A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch Osteoporos. 2019;15:1.
Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595-611.
Briot K. Bone and glucocorticoids. Ann Endocrinol (Paris). 2018;79:115-118.
Lespessailles E, Chapurlat R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int. 2020;31:1829-1834.
Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61:7-16.
Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Lupus erythematosus revisited Semin Immunopathol. 2016;38:97-112.
Salman-Monte TC, Torrente-Segarra V, Vega-Vidal AL, et al. Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): a systematic review. Autoimmun Rev. 2017;16:1155-1159.
Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued evolution. Int J Rheum Dis. 2015;18:242-249.
Hassanalilou T, Khalili L, Ghavamzadeh S, Shokri A, Payahoo L, Bishak YK. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. Auto Immun Highlights. 2017;9:1.
Islam MA, Khandker SS, Alam SS, Kotyla P, Hassan R. Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev. 2019;18:102392.
Hou C, Jin O, Zhang X. Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37:2699-2705.
Yuan Q, Xing X, Lu Z, Li X. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50:1022-1039.